An Economic Evaluation of Fluvastatin used for the Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention in the UK
- 1 January 2004
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 22 (8) , 525-535
- https://doi.org/10.2165/00019053-200422080-00004
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A single European currency for EQ-5D health statesThe European Journal of Health Economics, 2003
- Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation StudiesPharmacoEconomics, 2003
- Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary InterventionA Randomized Controlled TrialJAMA, 2002
- Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient CharacteristicsAnnals of Internal Medicine, 2000
- Cost-effectiveness of statinsThe American Journal of Cardiology, 1998
- Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group.1998
- Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.1998
- Therapeutic options and cost considerations in the treatment of ischemic heart disease.Cardiovascular Drugs and Therapy, 1998
- Is medical treatment for angina the most cost-effective option?European Heart Journal, 1997
- Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority populationBMJ, 1996